Compositions and methods of modulating receptor protein tyrosine phosphatases
AssigneeLa Jolla Institute for Allergy and Immunology
InventorsNunzio Bottini, Stephanie Stanford
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are compositions and methods of measuring levels of RPTP protein and RNA and treating subjects with certain diseases, such as autimmune diseases.
Claims30
A method of determining whether a subject has or is at risk of developing an autoimmune disease, said method comprising determining whether a subject expresses a modulated RNA level of an RPTP or a modulated protein level of an RPTP relative to a standard control, wherein the presence of said modulated RNA level or said modulated protein level indicates said subject has or is at risk of developing an autoimmune disease, wherein said RPTP is PTPRA, PTPRB, PTPRC, PTPRD, PTPRE, PTPRF, PTPRG, PTPRH, PTPRJ, PTPRK, PTPRM, PTPRN, PTPRN2, PTPRO, PTPRQ, PTPRR, PTPRS, PTPRT, PTPRU, PTPRV or PTPRZ1.
(canceled)
A method of treating a subject who has or is at risk of developing an autoimmune disease, said method comprising administering to said subject a therapeutically effective amount of an autoimmune therapeutic agent, wherein said autoimmune therapeutic agent is an agonist of an RPTP or an antagonist of an RPTP, wherein said RPTP is PTPRA, PTPRB, PTPRC, PTPRD, PTPRE, PTPRF, PTPRG, PTPRH, PTPRJ, PTPRK, PTPRM, PTPRN, PTPRN2, PTPRO, PTPRQ, PTPRR, PTPRS, PTPRT, PTPRU, PTPRV or PTPRZ1.
(canceled)
(canceled)
(canceled)
(canceled)
-30. (canceled)
A pharmaceutical composition comprising an autoimmune therapeutic agent and a pharmaceutically acceptable excipient, wherein said autoimmune therapeutic agent is an agonist or antagonist of an RPTP, wherein said RPTP is PTPRA, PTPRB, PTPRC, PTPRD, PTPRE, PTPRF, PTPRG, PTPRH, PTPRJ, PTPRK, PTPRM, PTPRN, PTPRN2, PTPRO, PTPRQ, PTPRR, PTPRS, PTPRT, PTPRU, PTPRV or PTPRZ1.
(canceled)
(canceled)
(canceled)
-42. (canceled)
Dependencies are inferred from the claim text.